Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).

Crit Care Explor · 2021 · PMC8601347 · PMID 34806021

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Time course of IL-10 was similar among the placebo group, cohort 1, and cohort 2, while cohort 3 showed a trend of a faster decline in IL-10 plasma concentrations during the first 12 hours after dosing.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.